Cardio Diagnostics Holdings Inc. · NASDAQ:CDIO
Cardio Diagnostics — Investor Presentation (February 2026)
26 slides from Cardio Diagnostics's investor presentation, Feb 19, 2026
Slide 1: Leading the Next Frontier in Precision Cardiovascular Medicine
Leading the Next Frontier in Precision Cardiovascular Medicine 2026 NASDAQ: CDIO 1
Slide 2: Disclaimer
Certain statements and information included in this presentation constitute "forward - looking statements" within the meaning of the Private Securities Litigation Act of 1995 . When used in this presentation, the words or phrases “will”, "will likely result," "expected to," "will continue," "anticip
Slide 3: Our Vision and Mission
Risk Assessment Early Diagnosis Risk Management Medical Management & Lifestyle Modifications Monitor Effectiveness Ongoing Evaluation Our Vision: Our Mission is to Make Cardiovascular Disease Prevention and Early Detection More Accessible, Personalized and Precise We envision a future where precisio
Slide 4: Corporate Highlights
To our knowledge, we have developed the first and only commercial solutions leveraging epigenetics and AI for cardiovascular disease prevention and early detection Over $176B TAM across Epi+Gen CHD and PrecisionCHD ⁽ ¹ ⁾ Commercially available, clinically validated tests, with growing adoption Stron
Slide 5: Leadership
Chairman President, Nutex Health, Inc. (NUTX) Co - founder of Astrana Health (ASTH) Director and former CEO of Clinigence Holdings (CLNH) MD from Georgetown University School of Medicine Warren Hosseinion, MD Leadership CEO & Director Co - founder of Cardio Diagnostics Co - inventor of the AI - Driv
Slide 6: Cardiovascular Disease Remains the Leading Cause of Death Globally Despite Largely Preventable
⁽ ¹ ⁾ World Health Organization ⁽ ² ⁾ American Heart Association ⁽ ³ ⁾ CDC $2T #1 Cardiovascular disease (CVD) is the leading cause of death globally, accounting for over 19 million deaths in 2022, or about 32% of all global deaths ⁽ ¹ ⁾ Following a healthy lifestyle may prevent ~80% of cardiovascul
Slide 7: The Burden of Cardiovascular Disease is Immense and Growing
⁽ ¹ ⁾ CDC ⁽ ² ⁾ Haidar, A et al., The American Journal of Cardiology Jan 2025, /doi.org/10.1016/j.amjcard.2024.10.003 ⁽ ³ ⁾ American Heart Association Employers Patients In the US, he art disease is responsible for approximately 920,000 deaths in 2023, which equates to 1 in every 3 deaths ⁽ ¹ ⁾ Card
Slide 8: Epigenetics + Genetics = An Individual's Unique Molecular Fingerprint
Epigenetics + Genetics = An Individual’s Unique Molecular Fingerprint We pioneered this approach to measure and quantify an individual’s unique molecular fingerprint to enable more precise clinical care EPIGENETICS (DNA METHYLATION) • Influenced by lifestyle & environment • Larger driver of risk for
Slide 9: Our AI-Driven Multi-Omics Engine Turns Molecular Biology Into Actionable Clinical Tests
Our AI - Dr iven Multi - Omics Engine Turns Molecular Biology Into Actionable Clinical Tests LARGE DATA • High quality clinical and molecular samples and database • Ongoing studies for interventions and new modalities DNA Bank & Databank Trade Secrets AI PLATFORM • Non - linear biomarker mining • Mu
Slide 10: Cardio Diagnostics' AI-Powered Clinical Tests
Cardio D iagnostics’ AI - Powered Clinical Tests Risk Stratification ⁽ ¹ ⁾ Diagnostic Aid ⁽ ² ⁾ To our knowledge, Epi+Gen CHD is the first and only commercially available blood test capable of assessing the three - year risk of a coronary heart disease event, including a heart attack To our knowledg
Slide 11: Epi+Gen CHD Risk Stratification Clinical Test
Epi+Gen CHD R isk Stratification Clinical Test cost savings per quality adjusted life year (QALY) ⁽ ³ ⁾ Up to $42K ⁽ ¹ ⁾ Internal estimate ⁽ ² ⁾ Dogan et al., 2021 Epigenomics ⁽ ³ ⁾ Jung Y et al., 2021, Epigenomics - cost savings were not calculated for a specific payer compared to the average sensi
Slide 12: PrecisionCHD Diagnostic Aid Clinical Test
PrecisionCHD D iagnostic Aid Clinical Test cost savings in the first year if PrecisionCHD used as the primary method of initial CHD assessment for one million lives ⁽ ³ ⁾ ~$113M ⁽ ¹ ⁾ Internal estimate ⁽ ² ⁾ Dogan et al., 2021 Epigenomics ⁽ ³ ⁾ Frisvold D et al., 2024, Advances in Therapy - cost sav
Slide 13: Our Tests Offer a Scalable, Novel Approach for Cardiovascular Disease Prevention and Detection
The use of Epi+Gen CHD and PrecisionCHD could save lives and reduce costs associated with cardiovascular disease Our Tests Offer a Scalable, Novel Approach for Cardiovascular Disease Prevention and Detection Not one and done Fast and convenient First - of - its - kind No exposure to ionizing radiati
Slide 14: INOCA Prevalence and Definition
• Up to ~70% of patients referred for coronary angiography due to angina and evidence of ischemia have no obstructive coronary arteries, and many have INOCA ⁽ ¹ ⁾ • Prevalence is particularly high in women ⁽ ¹ ⁾ What is INOCA ? • Ischemia with No Obstructive Coronary Arteries (INOCA) refers to patie
Slide 15: Dangers of INOCA and Why Imaging Misses It
• Standard imaging tests detect large - vessel blockages • Therefore, arteries often appear “normal,” leading to underdiagnosis Dangers of INOCA • Not a benign condition • Patients with INOCA have a comparable burden of symptoms: ⁽ ¹ ⁾ ⚬ reduced quality of life ⚬ high risk of adverse cardiovascular
Slide 16: PrecisionCHD Methylation vs Duke Jeopardy Scores Analysis
The Leverage plots from a Least Squares analysis of the relationship of PrecisionCHD methylation assessments, age and sex var iab les to Duke’s Jeopardy Scores in 267 subjects admitted to the University of Iowa for the care of Acute Coronary Syndrome. Data on INOCA for PrecisionCHD Presented at the
Slide 17: ACS and Mortality
• Acute Coronary Syndrome (ACS) is a sudden drop in blood flow to the heart that can cause a heart attack • ~1.4 million Americans are hospitalized with ACS each year ⁽ ¹ ⁾ • ACS patients have higher mortality than matched controls (47% vs. 39%) over a 12 year period of time ⁽ ² ⁾ PrecisionCHD and P
Slide 18: ACS Mortality is a Multi-Scale Problem
• DJS was better at predicting nearer - term (<8 months) mortality Time Dependent AUC of Mortality for ACS Patients ACS Mortality is a Multi - Scale Problem Data on ACS Patient Mortality Presented at the American College of Cardiology Conference • MSdPCR was better at predicting longer - term (>8 mo
Slide 19: Robust and Growing Evidence Base for Epi+Gen CHD and PrecisionCHD
Robust and Growing Evidence Base for Epi+Gen CHD and PrecisionCHD Rigorous clinical validation s in partnership leading health systems Economic evidence demonstrating cost effectiveness and cost savings Evidence demonstrating the utility of the tests to monitor treatment effectiveness Expand evidenc
Slide 20: A Highly Scalable Testing and Reporting Process
2a 2b 1a 1b REMOTE Telemedicine provider orders test for patient At - home lancet sample collection kit shipped to patient A Highly Scalable Testing and Reporting Process PROVIDER SETTINGS Lancet and/or vacutainer sample collection kits shipped to provider/healthcare organization Provider/healthcare
Slide 21: Internal CLIA Lab Recently Launched to Lower Costs and Increase Testing Capacity
Survey on Feb 10, 2026 found no deficiencies CLIA conditions met For DNA methylation assessments with high precision Utilize digital PCR with proprietary assays Space to increase infrastructure and automation to increase capacity Increased testing capacity Initial lab COGS reduction by ~30% with add
Slide 22: Epi+Gen CHD and PrecisionCHD U.S. Market Opportunity
Ep i+Gen CHD and PrecisionCHD U.S. Market Opportunity 40 - 60% target gross margin at scale $854 final CMS payment rate ~125B total addressable U.S. market ⁽ ¹ ⁾ 146M estimated eligible Americans ⁽ ¹ ⁾ $854 final CMS payment rate ~51B total addressable U.S. market ⁽ ¹ ⁾ 60 M estimated eligible Ameri
Slide 23: Commercial Targets in the U.S.
Commercial Targets in the U.S. Employers/Unions Offering remote and heart health fair options to drive engagement and utilization among employees Providers and Health Systems Telemedicine and onsite options primarily with internists, PCPs and preventive cardiologists Channel Partners Strat egic part
Slide 24: Opportunistic Global Expansion Through Partnerships
Opportunistic Global Expansion Through Partnerships Announced Partnership in India with Aimil Ltd and Dr. Lal PathLabs • Aimil to introduce PrecisionCHD to their extensive healthcare network • Dr. Lal PathLabs will be offering PrecisionCHD and has 290+ clinical labs and 300+ MD pathologists in their
Slide 25: Major Reimbursement Milestones Achieved and Underway for Both Tests
Major Reimbursement Milestones Achieved and Underway for Both Tests 0439U CPT PLA code $854 final CMS payment rate 0440U CPT PLA code $854 final CMS payment rate • Medicare cover age process is ongoing (final required step for Medicare) • Establishing out - of - network billing capability (expected
Slide 26: For more information, please email: investors@cdio.ai
For more information, please email: investors@cdio.ai 26
Cardio Diagnostics Holdings — Investor Presentation (February 2026) on 6ix